1. Home
  2. PHAR vs EVLV Comparison

PHAR vs EVLV Comparison

Compare PHAR & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$15.55

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Evolv Technologies Holdings Inc.

EVLV

Evolv Technologies Holdings Inc.

HOLD

Current Price

$5.17

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
EVLV
Founded
1988
2013
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PHAR
EVLV
Price
$15.55
$5.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$39.00
$9.13
AVG Volume (30 Days)
19.1K
3.3M
Earning Date
03-12-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.04
$15.27
Revenue Next Year
$2.70
$18.21
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$2.67
52 Week High
$21.34
$8.90

Technical Indicators

Market Signals
Indicator
PHAR
EVLV
Relative Strength Index (RSI) 42.58 44.67
Support Level $12.98 $4.81
Resistance Level $15.21 $5.81
Average True Range (ATR) 0.66 0.37
MACD -0.01 0.04
Stochastic Oscillator 21.99 46.34

Price Performance

Historical Comparison
PHAR
EVLV

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: